What is William Blair's Forecast for SLDB FY2026 Earnings?

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Equities researchers at William Blair issued their FY2026 earnings per share (EPS) estimates for shares of Solid Biosciences in a note issued to investors on Friday, March 7th. William Blair analyst S. Corwin expects that the company will earn ($2.76) per share for the year. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share.

Several other research firms also recently weighed in on SLDB. Chardan Capital reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Solid Biosciences in a report on Friday, March 7th. Citizens Jmp upgraded Solid Biosciences to a "strong-buy" rating in a research note on Tuesday, December 10th. HC Wainwright raised their price target on Solid Biosciences from $16.00 to $20.00 and gave the stock a "buy" rating in a research note on Monday. Truist Financial initiated coverage on Solid Biosciences in a research note on Wednesday, January 8th. They issued a "buy" rating and a $16.00 price target for the company. Finally, Wedbush started coverage on shares of Solid Biosciences in a research report on Friday, December 13th. They set an "outperform" rating and a $16.00 price objective on the stock. Nine research analysts have rated the stock with a buy rating and four have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $15.80.

Solid Biosciences Stock Down 10.0 %

SLDB stock traded down $0.58 during mid-day trading on Monday, reaching $5.16. The company had a trading volume of 796,375 shares, compared to its average volume of 2,795,252. The stock's 50-day simple moving average is $4.15 and its two-hundred day simple moving average is $5.47. Solid Biosciences has a one year low of $2.88 and a one year high of $15.05. The stock has a market capitalization of $393.42 million, a P/E ratio of -1.70 and a beta of 1.98.

Remove Ads

Institutional Trading of Solid Biosciences

Hedge funds have recently added to or reduced their stakes in the business. Vestal Point Capital LP lifted its holdings in shares of Solid Biosciences by 1.8% during the fourth quarter. Vestal Point Capital LP now owns 2,850,000 shares of the company's stock worth $11,400,000 after buying an additional 50,000 shares during the last quarter. Redmile Group LLC acquired a new position in Solid Biosciences during the 4th quarter valued at $2,461,000. D. E. Shaw & Co. Inc. bought a new stake in Solid Biosciences in the 4th quarter valued at $208,000. Corton Capital Inc. acquired a new stake in Solid Biosciences in the 4th quarter worth $41,000. Finally, Cubist Systematic Strategies LLC increased its holdings in shares of Solid Biosciences by 479.4% during the 4th quarter. Cubist Systematic Strategies LLC now owns 65,613 shares of the company's stock worth $262,000 after purchasing an additional 54,288 shares during the period. Institutional investors own 81.46% of the company's stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.